Off-label Prescribing Trends for ADHD Medications in Very Young Children

Area of Science:

• Pediatric pharmacology
• Medication safety
• Public health

Background:

• Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
• Medication is a primary treatment for ADHD, but prescribing patterns vary by age.
• Off-label prescribing is common in pediatrics, particularly for younger age groups.

Purpose of the Study:

• To examine off-label medication prescribing for Attention-Deficit/Hyperactivity Disorder (ADHD) in children covered by Medicaid.
• To analyze prescribing trends with a specific focus on very young children (under 6 years).

Main Methods:

• Observational cohort study utilizing retrospective analysis of Oregon Medicaid prescription data from 2012.
• Inclusion criteria: Children aged 3-18 years with ADHD and continuous Medicaid enrollment for at least 10 months.
• Off-label status determined by manufacturer prescribing information.

Main Results:

• A high percentage (91.4%) of ADHD medication prescriptions for children aged 3-5 years were off-label.
• Off-label prescribing significantly decreased to 21% for children over 5 years old.
• Concerns in the 3-5 year group included frequent alpha-agonist use, untested formulations (clonidine patches), atomoxetine, and high-dose stimulants.

Conclusions:

• The majority of Attention-Deficit/Hyperactivity Disorder (ADHD) medications used in very young children are prescribed off-label.
• This practice is concerning due to the lack of established safety and efficacy data for this vulnerable population.
• Further research is needed to ensure safe and effective ADHD treatment in young children.